Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Titel:
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Auteur:
Moro-Sibilot, D. Cozic, N. Pérol, M. Mazières, J. Otto, J. Souquet, P.J. Bahleda, R. Wislez, M. Zalcman, G. Guibert, S.D. Barlési, F. Mennecier, B. Monnet, I. Sabatier, R. Bota, S. Dubos, C. Verriele, V. Haddad, V. Ferretti, G. Cortot, A. De Fraipont, F. Jimenez, M. Hoog-Labouret, N. Vassal, G.